Last reviewed · How we verify
AEGR-733 and fenofibrate
AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor combined with fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, to reduce triglycerides and apolipoprotein B-containing lipoproteins.
AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor combined with fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, to reduce triglycerides and apolipoprotein B-containing lipoproteins. Used for Severe hypertriglyceridemia, Familial chylomicronemia syndrome.
At a glance
| Generic name | AEGR-733 and fenofibrate |
|---|---|
| Sponsor | Aegerion Pharmaceuticals, Inc. |
| Drug class | MTP inhibitor + fibrate combination |
| Target | Microsomal triglyceride transfer protein (MTP) and PPARα |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
AEGR-733 inhibits MTP, which is essential for the assembly and secretion of apolipoprotein B-containing lipoproteins, thereby reducing triglyceride and LDL levels. Fenofibrate acts as a PPARα agonist to further lower triglycerides and raise HDL cholesterol. The combination targets multiple pathways in lipid metabolism to achieve greater reductions in atherogenic lipoproteins.
Approved indications
- Severe hypertriglyceridemia
- Familial chylomicronemia syndrome
Common side effects
- Gastrointestinal disturbances (diarrhea, abdominal discomfort)
- Elevated liver enzymes
- Muscle-related adverse events
Key clinical trials
- Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS (PHASE2)
- Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AEGR-733 and fenofibrate CI brief — competitive landscape report
- AEGR-733 and fenofibrate updates RSS · CI watch RSS
- Aegerion Pharmaceuticals, Inc. portfolio CI